Evidence map›Paper›PMID 41368822›Full record

ArticlePolitics and the life sciences : the journal of the Association for Politics and the Life Sciences2026

Understanding biosafety practitioner perspectives.

David R Gillum, Christine Knight, Kathleen M Vogel

Abstract read
In one paragraph

Article in Politics and the life sciences : the journal of the Association for Politics and the Life Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Rethinking governance of synthetic cells.Frontiers in bioengineering and biotechnology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

David R GillumSchool of Public Health, https://ror.org/01keh0577University of Nevada, Reno, USA.ORCID 0000-0001-7732-1871
Christine KnightIndependent Research Consultant, Hope Valley, Derbyshire, England.
Kathleen M VogelSchool for the Future of Innovation in Society, https://ror.org/03efmqc40Arizona State University, USA.ORCID 0000-0002-8520-4402

Funding

SOS:BIO - Assessing U.S. Biosafety and Biosecurity Compliance for Potential Pandemic Pathogen Research and Dual Use Research of ConcernR01GM155913 · NIGMS · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI David Gillum, Kathleen Vogel · 2024 to 2026
$823k
NIGMS NIH HHS 1R01GM155913-01NIGMS NIH HHS R01 GM155913
6 · The paper itself

Abstract

In 2024, the U.S. Government introduced, and then quickly rescinded, a new policy to oversee Dual Use Research of Concern (DURC) and Pathogens with Enhanced Pandemic Potential (PEPP). This research explores how biosafety practitioners interpreted and assessed the policy itself and discussed challenges to implementation. An inductive, grounded theory approach was used to identify key insights from qualitative data generated at a 2-day deliberative workshop with 45 biosafety officers, compliance professionals and researchers; analysis was supported using NVivo software. Participants described the policy's ambiguous language, lack of actionable federal guidance, limited legal scope and unfunded administrative burdens as significant barriers to implementation. Although supportive of the policy's goals, workshop participants stressed the need for more precise definitions, practical examples and practitioner-informed implementation strategies. The findings demonstrate that durable and effective biosafety and biosecurity oversight requires early, substantive engagement with those operationalizing policy.

Indexed as

Containment of BiohazardsHumansPandemicsUnited Statesbiosafetybiosecuritydual use research of concernnational securitypolicypotential pandemic pathogens

Identifiers

PMID41368822
PMCPMC12825952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.